Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Duke University National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00352521 |
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also block blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may kill more tumor cells. Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating patients with recurrent malignant glioma and how well MRI predicts response to treatment.
Condition | Intervention | Phase |
---|---|---|
Brain and Central Nervous System Tumors |
Biological: bevacizumab Drug: irinotecan hydrochloride Procedure: dynamic contrast-enhanced magnetic resonance imaging |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas |
Estimated Enrollment: | 20 |
Study Start Date: | April 2006 |
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients receive bevacizumab IV and irinotecan IV on days 1, 15, and 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients also undergo dynamic contrast-enhanced MRI.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of any of the following malignant gliomas:
Recurrent disease
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, North Carolina | |
Duke Comprehensive Cancer Center | |
Durham, North Carolina, United States, 27710 |
Study Chair: | James J. Vredenburgh, MD | Duke University |
Study ID Numbers: | CDR0000481476, DUMC-8053-05-12R0 |
Study First Received: | July 13, 2006 |
Last Updated: | February 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00352521 History of Changes |
Health Authority: | United States: Food and Drug Administration |
adult anaplastic astrocytoma adult mixed glioma adult giant cell glioblastoma adult gliosarcoma recurrent adult brain tumor |
adult glioblastoma adult anaplastic ependymoma adult anaplastic oligodendroglioma adult pineal gland astrocytoma |
Glioblastoma Astrocytoma Irinotecan Bevacizumab Central Nervous System Neoplasms Angiogenesis Inhibitors Camptothecin Ependymoma Recurrence Brain Neoplasms |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neuroepithelioma Oligodendroglioma Glioma Gliosarcoma Antineoplastic Agents, Phytogenic Nervous System Neoplasms Neoplasms, Glandular and Epithelial |
Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Irinotecan Neoplasms, Nerve Tissue Physiological Effects of Drugs Central Nervous System Neoplasms Bevacizumab Neoplasms by Site Neoplasms, Germ Cell and Embryonal Therapeutic Uses Growth Inhibitors Glioma Angiogenesis Modulating Agents |
Nervous System Neoplasms Neoplasms by Histologic Type Growth Substances Nervous System Diseases Enzyme Inhibitors Angiogenesis Inhibitors Camptothecin Pharmacologic Actions Neuroectodermal Tumors Neoplasms Neoplasms, Neuroepithelial Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |